Mucin 1 (MUC1): A Multifaceted Target for Malignant Tumor Diagnosis, Therapy, and Translational Research

1. Concept

Mucins constitute a family of high-molecular-weight glycoproteins (>200 kDa), with nine identified members to date. Characterized by a peptide core and glycans (accounting for 50%-90% of their weight, primarily linked via O-glycosidic bonds), mucins play diverse roles in physiological and pathological processes. Mucin 1 (MUC1), a typical type I transmembrane protein, is predominantly expressed on the luminal or glandular surfaces of epithelial cells across various tissues and organs under physiological conditions, exhibiting an apical polar distribution. Recent research has expanded its expression profile to include multiple hematopoietic cells, such as T cells, B cells, and dendritic cells.

In the context of tumorigenesis and progression, MUC1 undergoes distinct abnormal alterations: ① marked overexpression, exceeding 100-fold that of normal tissues; ② loss of cell surface polarity, shifting from apical-specific to diffuse expression across the entire cell membrane; ③ structural modifications, mainly driven by abnormal glycosylation, which expose novel glycan structures and peptide epitopes. Notably, the MUC1 isoform MUC1/Y displays tumor-specific expression, being highly abundant in breast and ovarian cancer tissues while absent in adjacent normal tissues. These tumor-specific traits position MUC1 as a promising biological marker and a key target for tumor diagnosis and biotherapy.

2. Research Frontiers

Recent advances in MUC1 research have deepened our understanding of its molecular mechanisms, clinical applications, and translational potential. The MUC1 gene is localized on human chromosome 1q22, encoding a 1,255-amino-acid polypeptide backbone with three core functional domains: an extracellular region composed of 20-amino-acid tandem repeats (TR), each containing five potential O-glycosylation sites; a hydrophobic α-helical transmembrane domain; and a 72-amino-acid intracellular tail featuring multiple phosphorylation sites and protein interaction motifs. Abnormal overexpression and altered glycosylation of MUC1 are observed in over 90% of epithelial-derived malignancies, including breast, pancreatic, lung, ovarian, and colorectal cancers, making it a universal target for cancer intervention.

Mechanistically, research has uncovered that MUC1 exerts its oncogenic effects through multi-pathway crosstalk: interactions between the intracellular domain (MUC1-CT) and key signaling molecules (β-catenin, p53, NF-κB) regulate pathways such as Wnt, p53, and NF-κB; abnormal glycosylation exposes immunogenic epitopes; and MUC1 facilitates metastasis, hypoxia adaptation, cell survival, and immune escape through diverse interactions and signaling cascades. Clinically, translational research focuses on molecular diagnosis (liquid biopsy based on MUC1), targeted therapy (immunotoxins, ADCs, CAR-T cells, vaccines), and prognostic evaluation. Emerging strategies aim to overcome current challenges, including tumor heterogeneity, glycosylation complexity, and immunosuppressive microenvironments, through multi-epitope targeting, glycosylation-specific CAR-T cells, nanocarrier-based co-delivery, and epigenetic regulation.

3. Research Significance

MUC1 holds profound significance in malignant tumor research and clinical practice, addressing critical unmet needs in diagnosis, treatment, and prognosis. As a diagnostic marker, MUC1-based liquid biopsy technologies—such as serum MUC1 fragment detection (CA15-3, CA27.29) and circulating tumor cell MUC1 expression analysis—enable non-invasive monitoring of treatment efficacy and early warning of recurrence. CA15-3, the first FDA-approved breast cancer biomarker, remains a cornerstone of clinical management.

Therapeutically, MUC1-targeted strategies offer precision approaches to combat epithelial-derived tumors, minimizing off-target effects by leveraging tumor-specific expression. Vaccines targeting MUC1 tandem repeats have demonstrated promising immunogenicity in pancreatic cancer clinical trials, while ADCs and CAR-T cell therapies provide novel options for advanced or refractory cancers. Furthermore, understanding MUC1’s role in drug resistance and tumor stem cell maintenance opens new avenues for developing radical therapies. By decoding MUC1’s molecular mechanisms, researchers gain insights into tumor biology, including signaling regulation, immune escape, and microenvironment remodeling, laying the foundation for personalized medicine.

4. Related Mechanisms, Research Methods, and Product Applications

Mechanisms

MUC1 drives tumor progression through interconnected molecular mechanisms:

• Signaling Regulation: The intracellular domain (MUC1-CT) interacts with β-catenin, p53, and NF-κB, modulating pathways like Wnt, p53, and NF-κB. For example, phosphorylation of MUC1-CT stabilizes β-catenin, promoting nuclear translocation and activation of proliferation-promoting genes (cyclin D1, c-myc).
• Immunomodulation: Abnormal glycosylation of tumor-associated MUC1 (tMUC1) exposes epitopes (Tn, sialyl-Tn, TF antigens) recognized by the immune system, while MUC1 inhibits T cell activation and NK cell cytotoxicity to mediate immune escape.
• Tumor Progression: MUC1 interacts with adhesion molecules (e.g., ICAM-1) to facilitate metastasis, regulates HIF-1α for hypoxia adaptation, activates the PI3K/AKT/mTOR pathway to enhance cell survival, and modulates the tumor microenvironment via exosomes.

Research Methods and Product Applications

ANT BIO PTE. LTD. offers a comprehensive portfolio of MUC1-related products, including high-quality antibodies (under the Starter sub-brand) and recombinant proteins (under the UA sub-brand), designed to support MUC1 research across molecular mechanisms, diagnosis, and therapeutic development:

• Antibody Applications:
• MUC1/EMA Mouse mAb (SDT-777-37) and S-RMab® MUC1/EMA Recombinant Rabbit mAb (SDT-776-49) enable precise immunohistochemical staining and Western blotting for MUC1 expression analysis in tumor tissues, supporting pathological diagnosis and molecular typing.
• MUC17 Recombinant Rabbit mAb (SDT-1415-49) facilitates research on MUC1 family members, expanding insights into mucin-mediated tumorigenesis.
• Recombinant Protein Applications:
• CA125/MUC16 His Tag Protein (Human) and MUC18/CD146 His Tag Protein (Cynomolgus), expressed in HEK293 cells, retain native structural and glycosylation features. They are ideal for studying protein-protein interactions (e.g., MUC1-β-catenin binding), validating diagnostic antibodies, and screening MUC1-targeted therapeutics (ADCs, CAR-T cells).
• Translational Research Support: These products support liquid biopsy development (e.g., calibrating CA15-3/CA27.29 assays), vaccine design (evaluating immunogenicity of MUC1 epitopes), and mechanism studies (investigating MUC1-mediated signaling pathways via co-immunoprecipitation and cell-based assays).

5. Brand Mission

ANT BIO PTE. LTD. is committed to empowering the global life science community with innovative, high-quality reagents and solutions to accelerate scientific discovery and improve human health. We specialize in providing antibodies, recombinant proteins, ELISA kits, and general life science reagents through three dedicated sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Backed by advanced development platforms—including recombinant monoclonal antibody platforms (rabbit and mouse), rapid monoclonal antibody development, multi-system recombinant protein expression (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA Platform, and PTM Pan-Modification Antibody Platform—we adhere to stringent international certifications, including EU 98/79/EC, ISO9001, and ISO13485. Our mission is to be a trusted partner for researchers and clinicians worldwide, delivering reliable products and customized services that drive breakthroughs in cancer research, diagnostics, and therapeutics.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.